cystic fibrosis phase II trial

Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CFTM 1)Investigational compound BI ENaC inhibitor delivered twice daily via the Respimat ®, a handheld inhaler 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news